Rimexolone

Rimexolone
Clinical data
Trade names	Vexol
Other names	Trimexolone; Org 6216; 11β-Hydroxy-16α,17α,21-trimethylpregna-1,4-dien-3,20-dione
AHFS/Drugs.com	Monograph
MedlinePlus	a606003
Routes of; administration	Eye drops
ATC code	H02AB12 (WHO) S01BA13 (WHO);
Pharmacokinetic data
Elimination half-life	estimated 1–2 hours
Excretion	>80% faeces
Identifiers
	IUPAC name (8S,9S,10R,11S,13S,14S,16R,17S)-11-Hydroxy-10,13,16,17-tetramethyl-17-propanoyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one;
CAS Number	49697-38-3 ;
PubChem CID	5311412;
IUPHAR/BPS	7099;
DrugBank	DB00896 ;
ChemSpider	4470902 ;
UNII	O7M2E4264D;
KEGG	D05729 ;
ChEMBL	ChEMBL1200617 ;
CompTox Dashboard (EPA)	DTXSID4045474 ;
ECHA InfoCard	100.211.227
Chemical and physical data
Formula	C24H34O3
Molar mass	370.533 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C)C;
	InChI InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1 ; Key:QTTRZHGPGKRAFB-OOKHYKNYSA-N ;
	(what is this?) (verify)

Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye.^[1] It is marketed as a 1% eye drop suspension under the trade name Vexol by Alcon Laboratories, but was discontinued in the US and other countries.^[2]^[3]

Medical uses

Rimexolone is used to treat inflammation after eye surgery, to treat anterior uveitis, conjunctivitis and keratitis.^[2]^[3]

Contraindications

The substance is contraindicated in herpes simplex and most other viral eye infections, as well as mycobacterial, fungal and amoebal eye infections^[2]^[3] because it only reduces the inflammation but does not act against such microorganisms.

Side effects

The most common adverse effects are blurred vision, tearing and other kinds of eye discomfort. Eye pain, eye oedema, headache, increased intraocular pressure and other side effects are seen in less than 1% of patients.^[2]^[3]

Pharmacology

Pharmacodynamics

As a glucocorticoid, rimexolone acts as an agonist of the glucocorticoid receptor.

Pharmacokinetics

A small amount of rimexolone is absorbed into the systemic circulation. On hourly treatment with the eye drops for a week, blood serum concentrations peaked at 150 pg/ml on average, with many patients remaining below the detection threshold of 80 pg/ml. The elimination half-life from the circulation is estimated at one to two hours; the substance is mainly (over 80%) excreted via the faeces.^[2]^[3]

References

^ Kavuncu S, Horoz H, Ardagil A, Erbil HH (August 2008). "Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery". Int Ophthalmol. 28 (4): 281–5. doi:10.1007/s10792-007-9131-0. PMID 17762913. S2CID 20772101.
^ ^a ^b ^c ^d ^e Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Vexol 1% (10 mg/ml)-Augentropfensuspension.
^ ^a ^b ^c ^d ^e Drugs.com: Monograph.

[pmid17762913-1] Kavuncu S, Horoz H, Ardagil A, Erbil HH (August 2008). "Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery". Int Ophthalmol. 28 (4): 281–5. doi:10.1007/s10792-007-9131-0. PMID 17762913. S2CID 20772101.

[AC-2] Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Vexol 1% (10 mg/ml)-Augentropfensuspension.

[Drugs.com-3] Drugs.com: Monograph.

[1]

[2]

[3]